In order to make the management of incidents relating to access to the employee portal quicker and easier for everyone, we have set up an email address to which you can write to.
If your issue is:
I don’t know or I have forgotten my user name
I don’t know or I have forgotten my password
User blocked
I have changed or want to change my contact email address on the portal
Indicate your name, surname, ID number and explain your incident. The agency will resolve your request as soon as possible.
Remember that this email is only for incidents related to accessing the portal. If you have any queries about your payroll, you should continue to direct them to the HR Department at your head office.
ROVI has completed his first participation in the annual Congress of the German Society of Psychiatry, Psychotherapy, Psychosomatic and Neurology (DGPPN) with a high presence and activity with specialists in the area of Psychiatry.
Present with a team of more than 20 people and with an Okedi ® stand that reflected our high commitment to Psychiatry and schizophrenia, ROVI completed his participation in the congress by attending more than 300 meetings with psychiatrists and carrying out more than 200 practical demonstrations on the management and administration of risperidone ISM®, marketed in Germany, the United Kingdom and Spain since 2022.
In addition, ROVI collaborated with the satellite symposium “Schizophrenia exacerbation: time for change?“, dedicated to the therapeutic approach of non-adherent patients with schizophrenia who have been admitted due to a relapse led by Prof. Dr. Christoph Correll (Berlin, New York), Dr. Daniel Schöttle (Hamburg) and Prof. Dr. Anne Karow (Hamburg), important opinion leaders and national references in schizophrenia. During the symposium, a review of the clinical development of Okedi® was conducted, showing the main short- and long-term efficacy and tolerability results of the phase III clinical trial PRISMA-3 in the treatment of patients with non-adherent schizophrenia who have been admitted for relapse. This symposium was attended by 250 specialists in person and more than a hundred through streaming connection.
The congress, held from 23 to 26 November in Berlin (Germany), is considered one of the reference appointments of Psychiatry, bringing together 8,400 psychiatrists mainly from Germany. “For ROVI, it represents a perfect opportunity to introduce Okedi ®, the new innovative ILD antipsychotic based on our ISM® technology, and our commitment to schizophrenia and psychiatry in the country, since these types of appointments allow for closer ties with psychiatry specialists from central European countries such as Germany, Switzerland and Austria,” said ROVI’s Business Unit Director Psychiatry, Dr. Stefan Peters.
